929 results on '"Kukreti, Vishal"'
Search Results
2. The Impact of CD34+ Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma
3. Very late relapse in Hodgkin lymphoma: Characterizing an understudied population
4. Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre‐autologous stem cell transplant in relapsed/refractory diffuse large B‐cell lymphoma—outcome of rituximab‐dose‐intensive cyclophosphamide, etoposide, cisplatin (R‐DICEP) versus R‐GDP
5. A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
6. Post Salvage Therapy Autologous Transplant for Relapsed Myeloma, Ongoing Relevance within Modern Treatment Paradigms?
7. Predicting the Risks of Aggressive-Intent Chemotherapy Toxicity in Older Patients With Lymphoma: A Prospective Observational Pilot Study
8. Light Chain Amyloidosis (AL) Associated With B Cell Lymphoma a Single Center Experience
9. Implementation and Impact of Choosing Wisely Recommendations in Oncology
10. A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score
11. Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras
12. Addition of Cyclophosphamide “On Demand” to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma—A Retrospective Review of a Single-center Experience
13. The Impact of CD34+ Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma.
14. Implementation of medication reconciliation in outpatient cancer care
15. Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation
16. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
17. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis
18. Impact of a Training Program on Oncology Nurses’ Confidence in the Provision of Self-Management Support and 5As Behavioral Counseling Skills
19. Feasibility and Effectiveness of Self-Management Education and Coaching on Patient Activation for Managing Cancer Treatment Toxicities
20. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
21. Chemotherapy with stem cell transplantation is more effective than immunotherapy in sporadic late onset nemaline myopathy with monoclonal gammopathy
22. Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma
23. The I-Can Manage web-based cancer self-management program targeting treatment toxicities and health behaviours: Human centred co-design approach and cognitive-think aloud usability testing (Preprint)
24. Human centered co-design and usability testing of a web-based cancer self-management education program (I-Can Manage) targeting treatment toxicities and health behaviours (Preprint)
25. Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma
26. Clinical Characteristics and Disease Outcomes in Primary Bone Lymphoma: Retrospective Study
27. Frailty in Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR T) Therapy at Princess Margaret Cancer Centre: A Prospective Pilot Study
28. Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation
29. Crebbp Mutations Are Associated with Shorter Time to Progression in Limited-Stage Follicular Lymphoma Treated with Radiation
30. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma
31. Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma
32. Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study
33. Ambulatory Toxicity Management (AToM) Pilot: results of a pilot study of a pro-active, telephone-based intervention to improve toxicity management during chemotherapy for breast cancer
34. Clinical utility of interim CT scans in patients receiving chemoimmuntherapy for first line treatment of follicular lymphoma
35. Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma
36. From Choosing Wisely to Implementing Wisely in Cancer Care: A Scoping Review
37. Five hematologic tests and treatments to question
38. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis
39. Bridging Efforts to Longitudinally Improve and Evaluate VEnous thromboembolism prophylaxis uptake in hospitalized cancer patients through Interprofessional Teamwork (BELIEVE IT): A study by Princess Margaret Cancer Centre
40. The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question
41. Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume
42. Rapidity and Quality of Response to Steroid-Based Induction Therapy, Without the Addition of Novel Agents, Does Not Affect Post Transplant Outcomes in Multiple Myeloma
43. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
44. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
45. Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival
46. Publisher Correction: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
47. Overview of Head and Neck Lymphomas
48. Kinetics of response to first‐ and second‐line therapies in multiple myeloma: Assessment by both M‐spikes and light chains
49. Outcomes in Relapsed/Refractory Burkitt Lymphoma: A Multi-Centre Canadian Experience
50. Risk Stratification for Relapsed/Refractory Classical Hodgkin Lymphoma Integrating Pretransplant Deauville Score and Residual Metabolic Tumor Volume
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.